A phase 3 clinical trial presented at the American Heart Association’s 2025 Scientific Sessions reveals that enlicitide, an investigational oral PCSK9 inhibitor, reduces LDL cholesterol by up to 60% in high-risk cardiovascular patients, potentially offering an effective alternative to injectable PCSK9 inhibitors.
The CORALreef Lipids trial demonstrates that daily oral administration achieves lipid reduction comparable to current injection-only therapies, potentially addressing adherence challenges associated with chronic cardiovascular disease management. This development represents a significant advancement in lipid-lowering therapeutics, particularly for patients with established cardiovascular disease or high risk of heart attack and stroke.
Trial Design and Participant Profile
The multicenter, international study enrolled 2,912 adults (average age 63, 39% female) across 168 healthcare centers in 14 countries between August 2023 and July 2025. Participants included individuals with previous heart attacks or strokes, or those assessed as having moderate-to-high risk for cardiovascular events within 10 years.
All participants maintained elevated LDL levels despite stable lipid-lowering therapy, including 97% on statins and 26% taking additional cholesterol absorption inhibitors like ezetimibe. Participants were randomized 2:1 to receive either 20mg enlicitide once daily or placebo.
Efficacy Results and Comparative Performance
After 24 weeks of daily treatment, enlicitide demonstrated robust lipid-lowering effects:
- 60% reductionin LDL cholesterol, sustained through 52 weeks
- 53% decreasein non-HDL cholesterol
- 50% reductionin ApoB levels
- 28% loweringof Lp(a), a genetically determined cardiovascular risk factor
Notably, 70% of treated participants achieved both ≥50% LDL reduction and LDL levels <70 mg/dL, while over two-thirds reached the more stringent <55 mg/dL target. “The lipid changes with enlicitide were nearly identical to injectable PCSK9 antibodies and numerically superior to siRNA alternatives,” stated lead investigator Dr. Navar.
Safety Profile and Tolerability
The oral therapy demonstrated a favorable safety profile with serious adverse events occurring in 10% of enlicitide recipients versus 12% in the placebo group. Discontinuation rates due to side effects were low and comparable between groups (3% vs 4%), indicating good treatment tolerability. These findings support enlicitide’s potential as a well-tolerated addition to current lipid-lowering regimens.
Clinical Implications and Patient Impact
“This oral alternative could significantly improve treatment adherence, which remains a major challenge in long-term cardiovascular prevention,” explained Dr. Navar.
The convenience of daily oral administration may address barriers associated with injectable therapies, particularly for patients requiring intensive lipid management despite maximal statin therapy. The ability to significantly reduce multiple atherogenic lipoproteins, including the genetically determined Lp(a), represents an important therapeutic advantage.
Future Directions and Ongoing Research
The CORALreef outcomes trial continuation will determine whether enlicitide’s substantial lipid-lowering effects translate into reduced major cardiovascular events.
If successful, this oral PCSK9 inhibitor could transform management for high-risk patients who currently rely on injectable options, potentially improving both accessibility and adherence in chronic cardiovascular disease management.
Related topics:
